ArticleThe journal of allergy and clinical immunology. Global2026
Predicting outcomes of hazelnut oral food challenge: Pediatric cohort analysis.
Article in The journal of allergy and clinical immunology. Global, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Taste aversion and adverse events contribute equally to OIT discontinuation in children: A real-world multi-allergen analysis.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hazelnut is a common trigger of IgE-mediated food allergy in children, but clinical tolerance remains difficult to predict. While molecular diagnostics and guideline-based cutoffs offer valuable insights, their real-world applicability across heterogeneous populations is uncertain. Objective: Predictors of outcomes in pediatric hazelnut oral food challenges (OFCs) were evaluated to assess the diagnostic utility of clinical risk assessment and molecular markers. Methods: We conducted a single-center cohort study of 190 OFCs performed between 2022 and 2025. Clinical indication, prechallenge risk classification, laboratory markers, and predefined cofactors were prospectively documented. Outcomes were stratified by tolerance and intolerance. Predictive values for Cor a 14, hazelnut-specific IgE, skin prick test, and physician risk assessment were analyzed. Common thresholds and European Academy of Allergy and Clinical Immunology cutoffs were used. Results: Overall, 56% of OFCs were tolerated and 44% resulted in confirmed allergy. Cor a 14 ≥ 0.64 kU Conclusion: Cor a 14 and physician risk assessment reliably predict hazelnut OFC outcomes and guide personalized care. OFCs remain essential for diagnostic clarification and shared decision-making in pediatric allergy practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.